Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...
Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...
The advisory committee, which met at the FDA’s request Thursday, did not reach a conclusion about the cause of a safety ...
Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future
Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children ...
The FDA has since put a hold on enrolling children under 2 years old and those ages 2 through 5 who have never been exposed ...
A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...
MedPage Today on MSN2d
FDA Advisors Say More Data Needed for RSV Vaccines in Young KidsFDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of ...
The FDA has placed a hold on all clinical studies of vaccines for respiratory syncytial virus in infants due to safety concerns following a trial involving two mRNA-based vaccine candidates from ...
challenging to see how Moderna generates >$2bn per annum from a COVID shot. There is also debate around what age groups ought to receive an RSV vaccine, and this could be an area where the HHS ...
The S&P 500 fell 0.3% on Tuesday, Dec. 10, as the cooldown from last week's record-setting rally continued ahead of key ...
The Southern Hemisphere’s only mRNA manufacturing facility has opened in Victoria to ensure world-class mRNA vaccines and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback